石榴汁对COVID-19患者炎症标志物和全血细胞计数影响的随机临床试验方案
本研究为随机、安慰剂对照、双盲、平行两组(1:1)临床试验,纳入伊朗亚苏季市医院收治的轻中度COVID-19住院患者,旨在探究石榴汁对炎症标志物(CRP、IL-6、ESR)和全血细胞计数的影响。干预组接受500 ml石榴汁加标准治疗,对照组接受500 ml红色水安慰剂加标准治疗,每日两次,持续14天。计划样本量48例,每组24例。
要点
- 石榴汁500 ml每日两次联合标准治疗,对照为红色水安慰剂,疗程14天。
- 主要结局为治疗14天后CRP、IL-6、ESR及全血细胞计数水平。
- 纳入标准为RT-PCR确诊COVID-19的18岁及以上住院患者。
核心结论
- 该方案旨在评估石榴汁对轻中度COVID-19住院患者炎症标志物和全血细胞计数的疗效,尚待试验完成后得出结论。
研究设计与样本
- 随机、安慰剂对照、双盲、平行两组(1:1)临床试验,计划纳入48例患者,每组24例。
- 随机化采用8个区组长度为6的置换区组,按性别和年龄分层,由试验药师用计算机生成随机序列。
- 盲法为参与者与研究者双盲,石榴汁与安慰剂包装于相同瓶子,随机序列封存于不透明密封信封。
关键数值与推荐
- 干预组:500 ml石榴汁加COVID-19标准住院治疗;对照组:500 ml红色水安慰剂加标准治疗;均每日两次(午餐和晚餐后),持续14天。
- 主要结局:治疗14天后炎症标志物CRP、IL-6、ESR及全血细胞计数水平。
- 纳入标准:知情同意、年龄≥18岁、RT-PCR确诊COVID-19。
- 排除标准:妊娠或哺乳、IgA水平<61 mg/dl、弥散性血管内凝血或其他凝血病、严重充血性心力衰竭、入组前30天内参加其他临床试验。
- 终止标准:转入ICU、死亡、不愿继续参与。
临床怎么用
- 该方案为研究设计,尚不能提供临床实践推荐;若试验完成,可能为石榴汁辅助治疗COVID-19炎症提供证据。
局限性
- 样本量较小(48例),可能限制统计效能和结果外推。
- 试验注册为回顾性注册(2021年2月28日注册,招募同日开始)。
- 研究限于伊朗亚苏季市医院轻中度COVID-19住院患者,结果可能不适用于其他人群或疾病严重程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study is conducted to investigate efficacy of pomegranate juice on inflammatory biomarkers, C-reactive protein (CRP), interleukin 6(IL-6), erythrocyte sedimentation rate (ESR) and complete blood count (CBC) in hospitalized patients with mild to moderate coronavirus disease 2019 (COVID- 19). TRIAL DESIGN: This is a randomized, placebo-controlled, double-blind, parallel 2-arm (1:1 ratio) clinical trial. PARTICIPANTS: Patients with COVID-19 admitted to hospitals in Yasuj City, Kohgiluyeh and Boyer-Ahmad Province, Iran. INCLUSION CRITERIA: Informed consent Patients 18 years of age or older Diagnosis of COVID-19 based on real-time polymerase chain reaction (RT-PCR) test EXCLUSION CRITERIA: Pregnancy or lactation Immunoglobulin A (IgA) level <61 mg/dl Disseminated intravascular coagulation or any other types of coagulopathy Severe congestive heart failure Participation in any clinical trial within 30 days prior to enrollment in this RCT Other contraindications determined by the specialist. INTERVENTION AND COMPARATOR: Intervention: 500 ml pomegranate juice and standard of care hospital treatment for COVID-19 Comparator: matching placebo containing 500 ml of red water and standard of care hospital treatment for COVID-19 Both intervention and comparator to be taken twice a day, after lunch and dinner, for 14 days. CRITERIA FOR DISCONTINUING: Transfer of patients to intensive care unit (ICU) Death Unwillingness to continue participating in the study MAIN OUTCOMES: The main outcomes of this study are levels of inflammatory biomarkers, CRP, IL-6, ESR, and CBC after 14 days of treatment. RANDOMIZATION: Eligible patients will be randomly assigned into the intervention or control group in a 1:1 ratio. Randomization will be performed based on 8 permuted blocks with block sizes of 6 and they will be stratified according to sex and age categories. Randomization sequences will be prepared by the trial's pharmacist using computer-generated random numbers. BLINDING (MASKING): This study is a double-blind clinical trial (participant, researcher). The pomegranate juice and placebo juice are packaged in identical bottles, and the researcher and all the patients will be unaware of the study assignment until the end of the study. To ensure blinding, the randomization sequences will be kept in identical, opaque, sealed, and sequentially numbered envelopes. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): The calculated total sample size is 48 patients, with 24 patients assigned into each group. TRIAL STATUS: The protocol is Version 1.0, on March 3, 2021. Recruitment started on February 28, 2021, and is anticipated to be completed by May 21, 2021. TRIAL REGISTRATION: The Name of registering trial Effects of Pomegranate Juice (Punica Granatum) on Inflammatory Biomarkers and CBC in Patients with COVID-19: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Iranian registry of clinical trials (IRCT) Registration Number: IRCT20150711023153N2 Date of Trial Registration February 28, 2021, retrospectively registered FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials҆ website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Yousefi M, Sadriirani M, PourMahmoudi A, et al. Effects of pomegranate juice (Punica Granatum) on inflammatory biomarkers and complete blood count in patients with COVID-19: a structured summary of a study protocol for a randomized clinical trial. Trials. 2021. PMID: 33810808. doi:10.1186/s13063-021-05194-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。